Preview

Научно-практическая ревматология

Расширенный поиск

РАЦИОНАЛЬНОЕ ИСПОЛЬЗОВАНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

https://doi.org/10.14412/1995-4484-2018-1-29

Полный текст:

Аннотация

В 2015 г. экспертами, представляющими различные врачебные ассоциации России, были разработаны клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Создание этих рекомендаций было направлено на улучшение использования НПВП – наиболее востребованного в нашей стране средства для лечения боли при острых и хронических заболеваниях. Основной целью данной работы было снижение частоты потенциально опасных «класс-специфических» осложнений, которые могут возникать на фоне приема НПВП. Для этого был предложен алгоритм выбора НПВП, основанный на оценке факторов риска осложнений, индивидуальных особенностей различных представителей этой лекарственной группы и возможности медикаментозной профилактики.

За прошедшее время были получены новые данные, касающиеся эффективности и безопасности НПВП. Это потребовало пересмотра и дополнения ряда положений рекомендаций 2015 г. Представляется, что новая версия рекомендаций, созданная на основании анализа большого числа клинических и эпидемиологических исследований, их метаанализа, с учетом клинического опыта и мнения ведущих мировых экспертов, более полно представляет основные аспекты применения НПВП в реальной клинической практике.

Рекомендации предназначены для врачей всех специальностей.

Об авторах

А. Е. Каратеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

заведующий лабораторией патофизиологии боли и полиморфизма скелетно-мышечных заболеваний, докт. мед. наук,

115522, Москва, Каширское шоссе, 34А



Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

научный руководитель, 115522, Москва, Каширское шоссе, 34А;

заведующий кафедрой ревматологии ИПО, 119991, Москва, ул. Трубецкая, 8, стр. 2,

президент Ассоциации ревматологов России, академик РАН, профессор, докт. мед. наук



В. Т. Ивашкин
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

заведующий кафедрой пропедевтики внутренних болезней лечебного факультета, директор Клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко, 119991, Москва, ул. Трубецкая, 8, стр. 2,

главный внештатный специалист гастроэнтеролог Минздрава России, президент Российской гастроэнтерологической ассоциации, академик РАН, докт. мед. наук, профессор



А. И. Мартынов
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
Россия

профессор кафедры госпитальной терапии №1 лечебного факультета, 127473, Москва, ул. Делегатская, 20, стр.1,

академик РАН, докт. мед. наук, профессор



Н. Н. Яхно
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

профессор кафедры нервных болезней лечебного факультета, директор научно-образовательного клинического центра неврологии, 119991, Москва, ул. Трубецкая, 8, стр. 2,

президент Российского общества по изучению боли, академик РАН, докт. мед. наук, профессор



Г. П. Арутюнов
ФГБОУ ВО «Российский научно-исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия

заведующий кафедрой пропедевтики внутренних болезней и лучевой диагностики, 117997, Москва, ул. Островитянова, 1,

главный внештатный специалист терапевт Департамента здравоохранения г. Москвы, член-корреспондент РАН, докт. мед. наук, профессор



Л. И. Алексеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

заведующая отделом метаболических заболеваний костей и суставов с центром профилактики остеопороза Минздрава России, 115522, Москва, Каширское шоссе, 34А,

докт. мед. наук, профессор



Г. Р. Абузарова
Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиала ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России
Россия

руководитель центра паллиативной помощи онкологическим больным, 125284, Москва, 2-й Боткинский проезд, 3,

докт. мед. наук



М. А. Евсеев
ФГБУ «Клиническая больница №1» Управления делами Президента РФ (Волынская)
Россия

научный руководитель по хирургии, 121352, Москва, ул. Староволынская, 10,

докт. мед. наук, профессор



М. Л. Кукушкин
ФГБНУ «НИИ общей патологии и патофизиологии» РАН
Россия

руководитель лаборатории фундаментальных и прикладных проблем боли, 125315, Москва, ул. Балтийская, 8,

ответственный секретарь Российского общества по изучению боли, докт. мед. наук, профессор



С. С. Копенкин
ГБОУ ВПО «Российский научно-исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия

доцент кафедры травматологии, ортопедии и военно-полевой хирургии, 117997, Москва, ул. Островитянова, 1,

канд. мед. наук



А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

врио директора, 115522, Москва, Каширское шоссе, 34А,

докт. мед. наук, профессор



Т. Л. Лапина
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

доцент кафедры пропедевтики внутренних болезней лечебного факультета, 119991, Москва, ул. Трубецкая, 8, стр. 2,

канд. мед. наук



Д. С. Новикова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

заведующая лабораторией ревмокардиологии, 115522, Москва, Каширское шоссе, 34А,

докт. мед. наук



Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

руководитель лаборатории системных ревматических заболеваний с группой гемореологических нарушений, 115522, Москва, Каширское шоссе, 34А,

докт. мед. наук



А. П. Ребров
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Россия

заведующий кафедрой госпитальной терапии лечебного факультета, 410012, Саратов, ул. Большая Казачья, 112,

докт. мед. наук, профессор



К. В. Скоробогатых
Университетской клиники головной боли
Россия

генеральный директор, 109028, Москва, Яузский бульвар, 10, стр. 2,

канд. мед. наук



Н. В. Чичасова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

профессор кафедры ревматологии ИПО, 119991, Москва, ул. Трубецкая, 8, стр. 2,

докт. мед. наук



Список литературы

1. Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65 [Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65 (In Russ.)]. doi: 10.14412/1995-4484-2016-247-265

2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X. Epub 2015 Aug 28.

3. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)]. ISBN 978-5-9704-4261-6.

4. Здравоохранение в России. 2017: Статистический сборник. Москва: Росстат; 2017. 170 с. [Zdravookhranenie v Rossii. 2017: Statisticheskii sbornik [Public health in Russia. 2017: Statistical Digest]. Moscow: Rosstat; 2017. 170 p. (In Russ.)]. ISBN 978-5-89476-448-1. http://www.gks.ru

5. Доступно по ссылке: https://www.iqvia.com/our-customers/pharmaceutical-manufacturers [Available from: https://www.iqvia.com/ our-customers/pharmaceutical-manufacturers].

6. Шостак НА, Рябкова АА, Савельев ВС, Малярова ЛН. Желудочно-кишечное кровотечение как осложнение гастропатий, связанных с приемом нестероидных противовоспалительных препаратов. Терапевтический архив. 2003;(5):70-4 [Shostak NA, Ryabkova AA, Savel'ev VS, Malyarova LN. Gastrointestinal bleeding as a complication of gastropathy associated with use of nonsteroidal antiinflammatory drugs. Terapevticheskii Arkhiv. 2003;(5):70-4 (In Russ.)].

7. Евсеев МА. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Русский медицинский журнал. 2006;(15):1099-107 [Evseev MA. NSAID-induced gastroduodenal ulcer complicated by bleeding. Russkii Meditsinskii Zhurnal. 2006;(15):1099-107 (In Russ.)].

8. Гельфанд БР, Проценко ДН, Бабаянц АВ, Каратеев АЕ. Острые кровотечения из верхних отделов желудочно-кишечного тракта: от эпидемиологии до формирования концепции консервативной терапии. Инфекции в хирургии. 2013;(4):11-7 [Gel'fand BR, Protsenko DN, Babayants AV, Karateev AE. Severe bleeding from the upper parts of the gastrointestinal tract: from epidemiology to the formation of the concept of conservative therapy. Infektsii v Khirurgii. 2013;(4):11-7 (In Russ.)].

9. Jafar W, Jafar AJN, Sharma A. Upper gastrointestinal haemorrhage: an update. Frontline Gastroenterol. 2016 Jan;7(1):32-40. doi: 10.1136/flgastro-2014-100492. Epub 2014 Oct 10.

10. Del Piano M, Bianco MA, Cipolletta L, et al. The «Prometeo» study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol. 2013 Apr;47(4):e33-7. doi: 10.1097/MCG. 0b013e3182617dcc

11. Nagasue T, Nakamura S, Kochi S, et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion. 2015;91(1):37-41. doi: 10.1159/000368810. Epub 2015 Jan 20.

12. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi: 10.18433/J3VW2F

13. Каратеев АЕ, Насонов ЕЛ, Яхно НН. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23

14. Насонов ЕЛ, Ивашкин ВТ, Яхно НН и др. Проект Национальных клинических рекомендаций (основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов» (По результатам совещания группы экспертов, г. Москва, 01.04.2017). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75 [Nasonov EL, Ivashkin VT, Yakhno NN, et al. Draft National Clinical Recommendations (main provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain «Rational Use of Non-steroidal Anti-Inflammatory Drugs» (Based on the results of a meeting of the expert group, Moscow, April 1, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-5-69-75

15. Доступно по ссылке: http://www.grls.rosminzdrav.ru/ [Available from: http://www.grls.rosminzdrav.ru/].

16. Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi: 10.1002/art.20698

17. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11): 1-278, iii. doi: 10.3310/hta12110

18. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi: 10.2174/1874312901206010006. Epub 2012 Apr 3.

19. Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, doubleblind, controlled study. Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.

20. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi: 10.1002/14651858.CD000396.pub3

21. Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5:CD009865. doi: 10.1002/14651858.CD009865.pub2

22. Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6:CD012095. doi: 10.1002/14651858.CD012095.pub2

23. Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;10:CD004233. doi: 10.1002/14651858. CD004233.pub4

24. Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017 Jul 8;390(10090):e21-e33. doi: 10.1016/S0140-6736(17)31744-0

25. Combe B, Velicitat P, Garzon N, Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001 Mar;50 Suppl 1:S10-6.

26. Neighbor ML, Puntillo KA. Intramuscular ketorolac vs oral ibuprofen in emergency department patients with acute pain. Acad Emerg Med. 1998 Feb;5(2):118-22. doi: 10.1111/j.1553-2712.1998.tb02595.x

27. Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995 Dec;26(6):682-6. doi: 10.1016/S0196-0644(95)70037-4

28. Wright JM, Price SD, Watson WA. NSAID use and efficacy in the emergency department: single doses of oral ibuprofen versus intramuscular ketorolac. Ann Pharmacother. 1994 Mar;28(3):309-12. doi: 10.1177/106002809402800301

29. Dougados M, Listrat V, Duchesne L, Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic. 1992 Nov 30;59(11):769-73.

30. Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71-9. doi: 10.1111/j.1399-6576.1998.tb05083.x

31. Motov S, Yasavolian M, Likourezos A, et al. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2017 Aug;70(2):177-84. doi: 10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16.

32. Fraquelli M, Casazza G, Conte D, Colli A. Non-steroid antiinflammatory drugs for biliary colic. Cochrane Database Syst Rev. 2016 Sep 9;9:CD006390. doi: 10.1002/14651858.CD006390.pub2 [Epub ahead of print].

33. Pathan SA, Mitra B, Cameron PA. A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Antiinflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic. Eur Urol. 2018 Apr;73(4):583-95. doi: 10.1016/j.eururo.2017.11.001. Epub 2017 Nov 22.

34. Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal antiinflammatory drugs for spinal pain: a systematic review and metaanalysis. Ann Rheum Dis. 2017 Jul;76(7):1269-78. doi: 10.1136/annrheumdis-2016-210597. Epub 2017 Feb 2.

35. Rossi L, Conen D. Intramuscular injections – an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31-32):1477-82 (In Germ.).

36. Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis» – Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295-6.

37. Frick S, Cerny A. Necrotizing fasciitis due to Streptococcus pneumoniae after intramuscular injection of nonsteroidal anti-inflammatory drugs: report of 2 cases and review. Clin Infect Dis. 2001 Sep 1;33(5):740-4. doi: 10.1086/322592 Epub 2001 Aug 6.

38. Adil M, Amin SS, Arif T. Nicolau's syndrome: A rare but preventable iatrogenic disease. Acta Dermatovenerol Croat. 2017 Oct;25(3):251-3.

39. Kim SK, Kim TH, Lee KC. Nicolau syndrome after intramuscular injection: 3 cases. Arch Plast Surg. 2012 May;39(3):249-52. doi: 10.5999/aps.2012.39.3.249. Epub 2012 May 10.

40. Luton K, Garcia C, Poletti E, Koester G. Nicolau Syndrome: three cases and review. Int J Dermatol. 2006 Nov;45(11):1326-8. doi: 10.1111/j.1365-4632.2006.02674.x

41. Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi: 10.1016/j.ejpain.2006.02.013. Epub 2006 May 8.

42. Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi: 10.1136/ard.2003. 020313. Epub 2004 Apr 13.

43. Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain. 2011 Jan;27(1):1-8. doi: 10.1097/AJP.0b013e3181ed0639

44. DeLemos B, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011 May;18(3):216-26. doi: 10.1097/MJT. 0b013e3181cec307

45. Innes G, Croskerry P, Worthington J, et al. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med. 1998 Jul-Aug;16(4):549-56. doi: 10.1016/S0736-4679(98)00044-4

46. O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, doubleblind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789-802. doi: 10.1177/147323000903700615

47. Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016 Jun;24(6):962-72. doi: 10.1016/j.joca. 2016.01.135. Epub 2016 Feb 1.

48. Кукушкин МЛ. Алгоритмы диагностики и лечения боли в спине. Русский медицинский журнал. 2014;(11):844-8. [Kukushkin ML. Algorithms for diagnosis and treatment of back pain. Russkii Meditsinskii Zhurnal. 2014;(11):844-8 (In Russ.)].

49. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2016 Oct 10. pii: S0140-6736(16)30970-9. doi: 10.1016/S0140-6736(16)30970-9

50. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Feb 14. doi: 10.7326/M16-2367

51. Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi: 10.1002/14651858. CD012087

52. Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan-Feb;8(1): 173-84. doi: 10.1016/j.spinee.2007.10.013

53. Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi: 10.2147/JPR.S6775. Epub 2012 Nov 28.

54. White AP, Arnold PM, Norvell DC, et al. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S131-43. doi: 10.1097/ BRS.0b013e31822f178f

55. Barrington JW, Halaszynski TM, Sinatra RS, et al. Perioperative pain management in hip and knee replacement surgery. Am J Orthop (Belle Mead NJ). 2014 Apr;43(4 Suppl):S1-S16.

56. Elmallah RK, Cherian JJ, Pierce TP, et al. New and Common Perioperative Pain Management Techniques in Total Knee Arthroplasty. J Knee Surg. 2016 Feb;29(2):169-78. doi: 10.1055/s0035-1549027. Epub 2015 Apr 18.

57. Regan DW, Kashiwagi D, Dougan B, et al. Update in perioperative medicine: practice changing evidence published in 2016. Hosp Pract (1995). 2017 Oct;45(4):158-64. doi: 10.1080/21548331.2017. 1359060. Epub 2017 Jul 28.

58. De Oliveira GS Jr, Agarwal D, Benzon HT. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg. 2012 Feb;114(2):424-33. doi: 10.1213/ANE.0b013e3182334d68. Epub 2011 Sep 29.

59. Cepeda MS, Carr DB, Miranda N, et al. Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial. Anesthesiology. 2005 Dec;103(6):1225-32. doi: 10.1097/00000542-200512000-00018

60. McDaid C, Maund E, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess. 2010 Mar;14(17):1-153, iii-iv. doi: 10.3310/hta14170

61. Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 1;32(16):1677-90. doi: 10.1200/JCO.2013. 52.8356. Epub 2014 May 5.

62. Rodriguez MJ, Contreras D, Galvez R, et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain. 2003 Jul;104(1-2):103-10. doi: 10.1016/S0304-3959(02)00470-0

63. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002 Jul;38(10):1358-63. doi: 10.1016/S0959-8049(02)00102-8

64. Pannuti F, Robustelli della Cuna G, Ventaffrida V, et al. A doubleblind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori. 1999 Mar-Apr;85(2):96-100.

65. Liu Z, Xu Y, Liu ZL, et al. Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol. 2017 Oct;22(5):980-5. doi: 10.1007/s10147-017-1133-y. Epub 2017 May 8.

66. Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017 Jan;31(1):26-34. doi: 10.1177/0269216316655746. Epub 2016 Jul 20.

67. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005180. doi: 10.1002/14651858. CD005180

68. Derry S, Wiffen PJ, Moore RA, et al. Oral nonsteroidal antiinflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017 Jul 12;7:CD012638. doi: 10.1002/14651858.CD012638.pub2

69. Reid J, Hughes CM, Murray LJ, et al. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med. 2013 Apr;27(4): 295-303. doi: 10.1177/ 0269216312441382. Epub 2012 Mar 26.

70. Luyten FP, Geusens P, Malaise M, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2007 Jan;66(1):99-106. doi: 10.1136/ard. 2006.052308. Epub 2006 Jun 30.

71. Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.

72. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl): S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

73. Qaseem A, Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. doi: 10.7326/M16-0570. Epub 2016 Nov 1.

74. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis2016-209707. Epub 2016 Jul 25.

75. Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/ 14651858.CD010120.pub2

76. Schumacher H, Boice J, Dahikh D, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-92. doi: 10.1136/bmj.324.7352. 1488

77. Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi: 10.1007/s10067-015-2991-1. Epub 2015 Jun 24.

78. Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.

79. Blachier M, Canoui-Poitrine F, Dougados M, et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013 Sep; 52(9):1686-93. doi: 10.1093/rheumatology/ket207. Epub 2013 Jun 13.

80. Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi: 10.1016/j.rdc. 2012.08.005. Epub 2012 Sep 15.

81. Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi: 10.1002/14651858.CD010952.pub2

82. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi: 10.1136/ annrheumdis-2016-210770. Epub 2017 Jan 13.

83. Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. doi: 10.1002/art.21054

84. Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S18-21. doi: 10.1016/j.semarthrit.2015.11.007. Epub 2015 Dec 2.

85. Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs. 2011 Jul 9;71(10):1259-79. doi: 10.2165/11592550-000000000-00000

86. Kneer W, Rother I, Rother M, et al. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf. 2009 Jan;4(1):5-10. doi: 10.2174/157488609787354468

87. Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, doubleblind, placebo-controlled study. Am J Sports Med. 2005 Apr; 33(4):515-23. doi: 10.1177/0363546504268135 Epub 2005 Feb 8.

88. Baraf HS, Gloth FM, Barthel HR, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, doubleblind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging. 2011 Jan 1;28(1):27-40. doi: 10.2165/11584880-000000000-00000

89. Derry S, Moore RA, Gaskell H, et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 Jun 11;(6):CD007402. doi: 10.1002/14651858.CD007402.pub3

90. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi: 10.2147/JPR.S75160. eCollection 2015.

91. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal AntiInflammatory Drugs. Gastroenterology. 2018 Feb;154(3):500-14. doi: 10.1053/j.gastro.2017.10.049. Epub 2017 Dec 6.

92. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3. doi: 10.1186/ar4175. Epub 2013 Jul 24.

93. Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-8. doi: 10.1159/ 000452356. Epub 2017 Jan 5.

94. Lain L. Proton pump inhibitor co-therapy with nonsteroidal antiinflammatory drugs – nice or necessary? Rev Gastroenterol Disord. 2004;4 Suppl 4:S33-41.

95. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004 Aug;50(8):2433-40. doi: 10.1002/art.20440

96. Brooks J, Warburton R, Beales IL. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis. 2013 Sep;4(5):206-22. doi: 10.1177/ 2040622313492188

97. Scheiman J. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. J Clin Gastroenterol. 2016 Jan;50(1):5-10. doi: 10.1097/MCG.0000000000000432

98. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007 Sep;5(9): 1040-5. doi: 10.1016/j.cgh.2007.04.031 Epub 2007 Jul 10.

99. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006 Mar;82(965):186-91. doi: 10.1136/ pgmj.2005.039586

100. Taki M, Oshima T, Tozawa K, et al. Analysis of risk factors for colonic diverticular bleeding and recurrence. Medicine (Baltimore). 2017 Sep;96(38):e8090. doi: 10.1097/MD.0000000000008090

101. Nagata N, Niikura R, Yamada A, et al. Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study. PLoS One. 2016 Mar 15;11(3):e0151332. doi: 10.1371/ journal.pone.0151332. eCollection 2016.

102. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22. doi: 10.1111/j.1365-2036.2007.03312.x

103. Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008 May;6(5):536-44. doi: 10.1016/j.cgh. 2007.12.023. Epub 2008 Jan 31.

104. Stein J, Connor S, Virgin G, et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016 Sep 21;22(35):7908-25. doi: 10.3748/wjg.v22.i35.7908

105. Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. Open Rheumatol J. 2012;6:44-9. doi: 10.2174/1874312901206010044. Epub 2012 May 11.

106. Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi: 10.1185/03007995.2011. 581274. Epub 2011 May 12.

107. Lanas A. A review of the gastrointestinal safety data – a gastroenterologist's perspective. Rheumatology (Oxford). 2010 May;49 Suppl 2:ii3-10. doi: 10.1093/rheumatology/keq058

108. Каратеев АЕ, Насонов ЕЛ. Неязвенная диспепсия, ассоциированная с приемом НПВП: возможность применения антацидных препаратов. Научно-практическая ревматология. 2003;41(2):28-30 [Karateev AE, Nassonov EL. Non-ulcer dyspepsia associated with NSAID intake: possibility of antacid drugs application. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(2):28-30 (In Russ.)]. doi: 10.14412/1995-4484-2003-765

109. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. doi: 10.1016/ S1542-3565(05)00980-8

110. Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009 Oct;65(10):963-70. doi: 10.1007/s00228-009-0719-3. Epub 2009 Aug 27.

111. Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015 Mar;50(3):255-63. doi: 10.3109/ 00365521.2014.966753. Epub 2014 Oct 14.

112. Hensley A, Beales IL. Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals (Basel). 2015 Sep 7;8(3): 512-24. doi: 10.3390/ph8030512

113. Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9 [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya 2003;12(1):64-9 (In Russ.)].

114. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2018 Feb 21. doi: 10.1111/bph.14167 [Epub ahead of print].

115. Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006 Mar;1(2):236-45. doi: 10.2215/CJN. 00890805. Epub 2006 Feb 1.

116. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004 Mar;43(3):525-30. doi: 10.1161/01. HYP.0000116221.27079.ea Epub 2004 Jan 19.

117. Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002;8(Suppl 15):83-91.

118. Harley C, Wagner S. The prevalence of cardiovascular risk factors in parients prescribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003;25:139-49. doi: 10.1016/S0149-2918(03)90017-8

119. Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgestic use and risk of hypertension in younger woman. Arch Intern Med. 2002;162:2204-8. doi: 10.1001/archinte.162.19.2204

120. Formam J, Stampfer M, Curhan G. Non-narcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005 Sep;46(3):500-7. doi: 10.1161/01.HYP.0000177437. 07240.70. Epub 2005 Aug 15.

121. Solomon D, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-5. doi: 10.1161/01.HYP.0000136134. 31846.83

122. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;284:1247-55. doi: 10.1001/jama.284.10.1247

123. Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006;119:255-66. doi: 10.1016/j.amjmed.2005.09.054

124. Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9

125. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

126. Aw T, Haas S, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-6. doi: 10.1001/archinte.165.5.ioi50013

127. Chan C, Reid C, Aw T, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332-41. doi: 10.1097/HJH.0b013e3283310dc9

128. Watkins J, Abbott E, Hensby C, et al. Attenuation of hypotensive effect of propranalol and thiaside diuretics by indomethacin. Br Med J. 1980;281:702-5. doi: 10.1136/bmj.281.6242.702

129. Polonia J, Boaventure J, Gama G, et al. Influence of nonsteroidal antiinflammatory drugs on renal function and 24-hour blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995;13:925-31. doi: 10.1097/00004872-199508000-00014

130. Wong D, Spence J, Lamki L, et al. Effect of nonsteroidal antiinflammatory drugs on control of hypertension of beta-blockers and diuretics. Lancet. 1986;1:997-1001. doi: 10.1016/S0140-6736 (86)91271-7

131. Baez M, Alvarez C, Weilder D. Effects of the non-steroidal antiinflammatory drugs, piroxicam or sulindac, on the antihypertensive action of propranolol and verapamil. J Hypertension. 1987; Suppl. 5:563-6.

132. Cinquegrani M, Liang C. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment. Clin Exp Hypertension. 1988;10:411-31. doi: 10.3109/10641968809033901

133. Hardy B, Bartle W, Myers M, et al. Effects of indomethacin on the pharmakokinetics of felodipine. Br J Clin Pharmacol. 1988;26:557-67. doi: 10.1111/j.1365-2125.1988.tb05295.x

134. Houston M, Weir M, Gray J, et al. The effects of non-steroidal antiinflammatory drugs on blood pressure of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155: 1049-54. doi: 10.1001/archinte.1995.00430100075009

135. Klassen D, Goadfriend T, Schuma A, et al. Assesment of Blood pressure during treatment with naproxen of ibuprofen in hypertensive patients treated with hydrochlorthiazide. J Clin Pharmacol. 1993;33(10): 971-8. doi: 10.1002/j.1552-4604.1993.tb01932.x

136. Johnson D, Hisel T, Phillips B. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003;37:442-6. doi: 10.1345/aph.1C277

137. Whelton A, Fort J, Puma J, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95. doi: 10.1097/00045391-200103000-00003

138. Whelton A, White W, Bello A, et al. SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systolic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63. doi: 10.1016/S0002-9149(02)02661-9

139. Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42:985-94. doi: 10.1177/0091270002042009005

140. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3): e372-82. Epub 2008 Oct 24.

141. Aljadhey H, Tu W, Hansen RA, et al. Comparative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012 Oct 24;12:93. doi: 10.1186/1471-2261-12-93

142. Villa J, Cano A, Franco D, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria. 2014 Nov;46(9):464-74 (In Span.). doi: 10.1016/j.aprim.2013.11.010. Epub 2014 Mar 22.

143. Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug;12(4):258-66. doi: 10.1007/ s11906-010-0120-8

144. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007 Jan 1;99(1):91-8. doi: 10.1016/ j.amjcard.2006.07.069. Epub 2006 Nov 10.

145. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539-41. doi: 10.1126/science.1068711

146. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J Clin Invest. 2006 Jan;116(1):4-15. doi: 10.1172/JCI27291

147. Schaeverbeke T, Heloire F, Deray G. How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006 Sep;35 Suppl 1:41-6. doi: 10.1016/S0755-4982(06)74939-9

148. Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Semin Arthritis Rheum. 2008 Dec;38(3):165-87. doi: 10.1016/j.semarthrit.2007. 10.004. Epub 2008 Jan 4.

149. Vonkeman HE, Brouwers JR, van de Laar MA. Understanding the NSAID related risk of vascular events. BMJ. 2006 Apr 15;332(7546):895-8. doi: 10.1136/bmj.332.7546.895

150. Fosbol EL, Kober L, Torp-Pedersen C, Gislason GH. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi: 10.1517/14740338.2010.501331

151. Boulakh L, Gislason GH. Treatment with non-steroidal antiinflammatory drugs in patients after myocardial infarction – a systematic review. Expert Opin Pharmacother. 2016 Jul;17(10): 1387-94. doi: 10.1080/14656566.2016.1186648. Epub 2016 May 23.

152. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27;113(25): 2906-13. doi: 10.1161/CIRCULATIONAHA.106.616219. Epub 2006 Jun 19.

153. Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015 Feb 24;313(8):805-14. doi: 10.1001/jama.2015.0809

154. Richman IB, Owens DK. Aspirin for Primary Prevention. Med Clin North Am. 2017 Jul;101(4):713-24. doi: 10.1016/j.mcna.2017. 03.004

155. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17. doi: 10.1056/NEJMoa003199

156. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. doi: 10.1016/j.jacc. 2005.01.045

157. Van Solingen RM, Rosenstein ED, Mihailescu G, et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med. 2001 Sep;111(4):285-9. doi: 10.1016/S0002-9343(01)00838-5

158. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthe volunteers. J Clin Pharmacol. 2002 Sep;42(9):1027-30. doi: 10.1177/ 0091270002042009010

159. Van Ryn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004 Jul;44(7):777-84. doi: 10.1177/0091270004266623

160. MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-4. doi: 10.1016/S0140-6736(03)12509-3

161. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, GonzalezPerez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004 Jun 22;109(24):3000-6. doi: 10.1161/01.CIR.0000132491.96623. 04. Epub 2004 Jun 14.

162. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefit of aspirin on first myocardial infarction by non-steroidal antiinflammatory drugs. Circulation. 2003 Sep 9;108(10):1191-5. doi: 10.1161/01.CIR.0000087593.07533.9B Epub 2003 Aug 25.

163. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol. 2005 Aug;32(8):1589-93.

164. Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction. BMJ. 2003 Dec 6;327(7427): 1322-3. doi: 10.1136/bmj.327.7427.1322

165. Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004 Apr 26;164(8):852-6. doi: 10.1001/archinte.164.8.852

166. Singh G, Graham D, Wang H, et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65 Suppl. II:61 (OP0024 abst).

167. Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Antiinflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Clin Cardiol. 2016 Feb;39(2):111-8. doi: 10.1002/clc.22502. Epub 2015 Dec 31.

168. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008 Nov; 10(11):1102-7. doi: 10.1016/j.ejheart.2008.07.013. Epub 2008 Aug 29.

169. Girouard C, Gregoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore). 2017 Mar;96(9):e6239. doi: 10.1097/MD. 0000000000006239

170. Hudson M, Richard H, Pilote L. Different in outcome of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005 Jun 11;330(7504):1370. doi: 10.1136/bmj.330.7504.1370

171. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005 May;44(5):677-80. doi: 10.1093/rheumatology/keh610. Epub 2005 Mar 22.

172. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in eldery patients: a population-based cohort study. Lancet. 2004 May 29;363(9423):1751-6. doi: 10.1016/S0140-6736(04)16299-5

173. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857

174. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003 Mar;14(2):240-6. doi: 10.1097/01.EDE. 0000034633.74133.C3

175. Bä ck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012 Aug;33(15):1928-33. doi: 10.1093/eurheartj/ehr421. Epub 2011 Nov 21.

176. Liu G, Yan YP, Zheng X, et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol. 2014 Nov 15;114(10):1523-9. doi: 10.1016/j.amjcard.2014.08.015. Epub 2014 Aug 27.

177. Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011 Jul 4;343:d3450. doi: 10.1136/bmj.d3450

178. Chuang SY, Hsu PF, Lin F, et al. Association between Nonsteroidal Anti-inflammatory Drugs and Atrial Fibrillation among a Middle-aged Population: A Nationwide Populationbased Cohort. Br J Clin Pharmacol. 2018 Mar 20. doi: 10.1111/ bcp.13558 [Epub ahead of print].

179. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6):669-81. doi: 10.1517/14740330903311023

180. Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal antiinflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi: 10.1186/s12882-017-0673-8

181. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi: 10.1053/j.ajkd.2004.12.005

182. Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 2013 Nov;62(5):1012-7. doi: 10.1053/j.ajkd.2013.03.045. Epub 2013 Jun 14.

183. Lipworth L, Abdel-Kader K, Morse J, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016 Nov 24;17(1):189. doi: 10.1186/s12882-016-0411-7

184. Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/ HYPERTENSIONAHA.114.05105. Epub 2015 Jul 13.

185. Mö ller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2013 Dec 19. doi: 10.1136/ annrheumdis-2013-204078 [Epub ahead of print].

186. Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013 Jun;30(3):247-55. doi: 10.1093/fampra/ cms086. Epub 2013 Jan 8.

187. Souter A. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg. 1994 Dec;79(6):1178-90. doi: 10.1213/00000539-199412000-00025

188. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and the risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82. doi: 10.1001/jama.1996.03530290046036

189. Weber EW, Slappendel R, Durieux ME, et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003 Dec;20(12):963-6. doi: 10.1097/00003643-200312000-00005

190. Bricker SR, Savage ME, Hanning CD. Perioperative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987 Nov;4(6):429-34.

191. Wierod FS, Frandsen NJ, Jacobsen JD, et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998 Apr;32(2): 120-2. doi: 10.1080/003655998750014495

192. Nikanne E, Kokki H, Salo J, Linna TJ. Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg. 2005 Feb;132(2):287-94. doi: 10.1016/j.otohns.2004.09.005

193. Moiniche S, Romsing J, Dahl JB, Tramrr MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: A quantitative systematic review. Anesth Analg. 2003 Jan;96(1):68-77. doi: 10.1213/00000539-200301000-00015

194. Forrest JB, Camu F, Greer IA, et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain re-lief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33. doi: 10.1093/bja/88.2.227

195. Deutsch D, Boustiere C, Ferrari E, et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol. 2017 Jun;10(6):495-505. doi: 10.1177/1756283X17702092. Epub 2017 Apr 17.

196. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-63. doi: 10.3748/ wjg.v23.i11.1954

197. Мороз ЕВ, Каратеев АЕ, Крюков ЕВ, Чернецов ВА. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675-84 [Moroz EV, Karateev AE, Kryukov EV, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675-684 (In Russ.)]. doi: 10.14412/1995-4484-2017-675-684

198. Elia N, Lysakowski C, Tramer MR. Does Multimodal Analgesia with Acetaminophen, Non-steroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone?: Meta-analyses of Randomized Trials. Anesthesiology. 2005 Dec;103(6):1296-304. doi: 10.1097/00000542-200512000-00025

199. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis. 2013 Nov;17(4):643-56, ix. doi: 10.1016/j.cld.2013.07.009. Epub 2013 Sep 4.

200. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010 Dec 7;16(45):5651-61. doi: 10.3748/wjg.v16.i45.5651

201. Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb;104(2):356-62. doi: 10.1038/ajg.2008.149. Epub 2009 Jan 27.

202. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. doi: 10.1016/j.clinthera.2006.08.014

203. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003 Jul 5;327(7405):18-22. doi: 10.1136/bmj.327.7405.18

204. Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi: 10.1111/bcp.12938. Epub 2016 Apr 27.

205. Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7

206. Каратеев АЕ. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium medicum. 2011; 13(9):89-95 [Karateev AE. Russian experience of nimesulide: review of clinical trials. Consilium medicum. 2011;13(9): 89-95 (In Russ.)].

207. Каратеев АЕ, Журавлева МВ. Анализ спонтанных сообщений российских врачей о неблагоприятных реакциях, возникших на фоне приема нимесулида: гепатотоксические осложнения очень редки. Эффективная фармакотерапия. 2015;(8):4-12 [Karateev AE, Zhuravleva MV. Analysis of spontaneous Russian doctors about the adverse reactions that occurred in patients receiving nimesulide: hepatotoxic complications are very rare. Effektivnaya Farmakoterapiya. 2015;(8):4-12 (In Russ.)].

208. Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008 Jan;15(1):15-21. doi: 10.1097/MOH.0b013e3282f15fb9

209. Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J. 2005 Sep 1;123(5):247-9. doi: 10.1590/S1516-31802005000500009 Epub 2005 Dec 8.

210. Mourad AA, Bahna S. Hypersensitivities to non-steroidal antiinflammatory drugs. Expert Rev Clin Immunol. 2014 Sep;10(9): 1263-8. doi: 10.1586/1744666X.2014.946905. Epub 2014 Aug 4.

211. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32. doi: 10.1111/all.12260. Epub 2013 Oct 5.

212. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588-94. doi: 10.1055/s-0032-1325618. Epub 2012 Oct 9.

213. Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. doi: 10.1007/s11882-004-0037-x

214. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2. doi: 10.1186/ar4174. Epub 2013 Jul 24.

215. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

216. Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):81-5. doi: 10.3760/cma.j.issn.0578-1426.2017.01.021

217. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010. 128660. Epub 2010 Sep 10.

218. Singh G, Triadafilopoulos S. Appropriative choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract. 2005 Oct;59(10):1210-7. doi: 10.1111/j.1368-5031.2005.00660.x

219. Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8): 1453-8. doi: 10.1136/ard.2009.123166. Epub 2010 May 24.

220. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl2016-312288. Epub 2016 Oct 5.

221. Huang J, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22. doi: 10.1016/ S0140-6736(02)07273-2

222. Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol. 2015 May;110(5):684-9. doi: 10.1038/ajg.2015.98. Epub 2015 Apr 21.

223. Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003. doi: 10.1016/S0195-668X(03)00114-3

224. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96. doi: 10.1177/2047487316653709. Epub 2016 Jun 27.

225. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.

226. Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi: 10.1186/ar4134

227. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17; 376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.

228. Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-82. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11.

229. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/ 11633470-000000000-00000

230. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi: 10.1371/ journal.pone.0190798. eCollection 2018.

231. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. doi: 10.1016/S0140-6736(07)60234-7

232. Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov;135(5):1517-25. doi: 10.1053/j.gastro.2008.07.067. Epub 2008 Aug 3.

233. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107:48-54. doi: 10.1016/S0002-9343(99) 00367-8

234. Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi: 10.1097/MD. 0000000000001592

235. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med. 2004 Jul 15;117(2):100-6. doi: 10.1016/j.amjmed.2004.03.012

236. Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):365-75. doi: 10.1002/pds.3385

237. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012

238. Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94 [Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94 (In Russ.)]. doi: 10.14412/1996-7012-2017-4-89-94

239. Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan; 130(1):55-71. doi: 10.1080/00325481.2018.1412799. Epub 2017 Dec 15.

240. Tacconelli S, Bruno A, Grande R, et al. Nonsteroidal antiinflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. Expert Opin Drug Saf. 2017 Jul;16(7):791-807. doi: 10.1080/14740338.2017.1338272. Epub 2017 Jun 8.

241. Antman EM. Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. Circulation. 2017 May 23;135(21):2062-72. doi: 10.1161/CIRCULATIONAHA.117. 027288

242. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086

243. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Safety. 2013;22:559-70. doi.org/10.1002/pds.3437

244. Eisner F, Hermann D, Bajaeifer K, et al. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience. Visc Med. 2017 Jun;33(3):221-6. doi: 10.1159/000475450. Epub 2017 Jun 16.

245. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031

246. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502

247. Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179. doi: 10.1186/s12916-016-0718-z

248. Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol. 2014 Dec; 12(4):398-413. doi: 10.1007/s11938-014-0029-4

249. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24.

250. Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jun;33(6):973-80. doi: 10.1080/03007995.2017.1281110. Epub 2017 Jan 25.

251. Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May;119(5):448.e27-36. doi: 10.1016/j.amjmed.2005.11.020

252. Каратеев АЕ. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013;51(3):332-40 [Karateev AE. Six stabs in the back of proton pump inhibitors. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):332-40 (In Russ.)]. doi: 10.14412/1995-4484-2013-1509

253. Maes ML, Fixen DR, Linnebur SA. Adverse effects of protonpump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017 Sep;8(9):273-97. doi: 10.1177/20420986 17715381. Epub 2017 Jun 29.

254. Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi: 10.1038/ nrgastro.2017.117. Epub 2017 Sep 20.

255. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr; 37(4):201-11. doi: 10.1007/s40264-014-0144-0

256. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. doi: 10.1038/clpt.2010.219

257. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.

258. Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 Jul;42(7):633-40. doi: 10.3109/ 00498254.2011.653655. Epub 2012 Feb 7.

259. Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7. doi: 10.1097/FJC.0b013e3181e19739

260. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9): 937-44. doi: 10.1001/jama.2009.261

261. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-8. doi: 10.1503/cmaj.082001

262. Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014 May;126(3):239-45. doi: 10.3810/pgm.2014. 05.2772

263. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol. 2006 Apr;101(4):701-10. doi: 10.1111/j.1572-0241.2006.00499.x Epub 2006 Feb 22.

264. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi: 10.1016/S0140-6736(07)60749-1

265. Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012;17:286-96. doi: 10.1111/j.1523-5378.2012.00942.x

266. Ивашкин ВТ, Маев ИВ, Лапина ТЛ и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):4-21 [Ivashkin VT, Maev IV, Lapina TL, et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and the resolution of the Expert Council of the Russian Gastroenterological Association on May 19, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):4-21 (In Russ.)].

267. Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018 May;34(3):175-82. doi: 10.1097/MOG. 0000000000000427

268. Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory DrugInduced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016 Jun;14(6):809-15.e1. doi: 10.1016/j.cgh.2015.10.022. Epub 2015 Oct 30.

269. Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015 Apr; 50(4):387-93. doi: 10.1007/s00535-014-1032-1. Epub 2015 Jan 10.

270. Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol. 2009;54:309-17. doi: 10.4166/kjg.2009.54.5.309

271. Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500-7. doi: 10.1007/s10620-008-0507-4

272. Мороз ЕВ, Каратеев АЕ. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология. 2016;10(4):97-105 [Moroz EV, Karateev AE. Rebamipide: Effective drug prevention of NSAID enteropathy is possible. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):97-105 (In Russ.)]. doi: 10.14412/1996-7012-2016-4-97-105

273. Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Dec 1. doi: 10.1007/s10620-017-4871-9 [Epub ahead of print].

274. Hasegawa M, Horiki N, Tanaka K, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013 Nov;23(6):1172-8. doi: 10.1007/s10165-012-0819-2. Epub 2013 Jan 10.

275. Park SH, Cho CS, Lee OY, et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled TrialSTORM STUDY. J Clin Biochem Nutr. 2007 Mar;40(2):148-55. doi: 10.3164/jcbn.40.148

276. Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014 Jul;8(4):371-9. doi: 10.5009/gnl. 2014.8.4.371. Epub 2013 Dec 24.

277. Kurokawa S, Katsuki S, Fujita T, et al. A randomized, doubleblinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014 Feb;49(2):239-44. doi: 10.1007/s00535-013-0805-2. Epub 2013 Apr 18.

278. Watanabe T, Takeuchi T, Handa O, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-tosevere small intestinal damage. PLoS One. 2015 Apr 15;10(4): e0122330. doi: 10.1371/journal.pone.0122330. eCollection 2015.

279. Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0. Epub 2013 Feb 28.

280. Yokoyama H, Ito N, Soeda S, et al. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther. 2013 Feb;38(1):12-5. doi: 10.1111/j.1365-2710.2012. 01373.x. Epub 2012 Aug 6.

281. Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013 May;109(5):825-33. doi: 10.1160/TH12-07-0532. Epub 2012 Dec 13.

282. Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013 Mar;69(3):365-71. doi: 10.1007/s00228-012-1370-y. Epub 2012 Aug 14.

283. Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6

284. Группа экспертов под председательством С.А. Бойцова и Н.В. Погосова. Российское кардиологическое общество. Национальное общество профилактической кардиологии. Российское общество профилактики неинфекционных заболеваний. Кардиоваскулярная профилактика 2017. Доступно по ссылке: http://ropniz.ru/wp-content/uploads/2017/11/CVP_2017. pdf [A panel of experts chaired by S.A. Boytsov and N.V. Pogosov. Russian Cardiology Society. National Society of Preventive Cardiology. Russian Society for the Prevention of Noncommunicable Diseases. Cardiovascular prevention 2017. Available from: http://ropniz.ru/wp-content/uploads/2017/ 11/CVP_2017.pdf].

285. Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018 Mar 6;168(5):351-8. doi: 10.7326/M17-3203. Epub 2018 Jan 23.

286. Рабочая группа членов Правления Научного общества нефрологов России под руководством А.В. Смирнова. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Санкт-Петербург: Левша; 2012. 51 с. [Working group of members of the Board of the Scientific Society of Nephrologists of Russia under the guidance of A.V. Smirnova. National recommendations. Chronic kidney disease: the basic principles of screening, diagnosis, prevention, and approaches to treatment. St. Petersburg: Levsha; 2012. 51 p.]. ISBN 978-5-93356-129-3

287. Рабочая группа под руководством Денисова И.Н. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации» Хроническая болезнь почек. Клинические рекомендации. Москва; 2014. Доступно по ссылке: http://sevgb6.ru/doc/ klinicheskie-rekomendacii/hbp.pdf [The working group, led by Denisov I.N. All-Russian Public Organization «Association of General Practitioners (Family Physicians) of the Russian Federation» Chronic kidney disease. Clinical recommendations. Moscow; 2014. Available from: http://sevgb6.ru/doc/klinicheskierekomendacii/hbp.pdf].

288. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4; 158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007

289. National Institute for Health and Care Excelence (NICE): Chronic kidney disease in adults: assessment and management. Available at: https://www.nice.org.uk/guidance/cg182 Accessed September 26th 2017.


Для цитирования:


Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П., Алексеева Л.И., Абузарова Г.Р., Евсеев М.А., Кукушкин М.Л., Копенкин С.С., Лила А.М., Лапина Т.Л., Новикова Д.С., Попкова Т.В., Ребров А.П., Скоробогатых К.В., Чичасова Н.В. РАЦИОНАЛЬНОЕ ИСПОЛЬЗОВАНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ. Научно-практическая ревматология. 2018;56:1-29. https://doi.org/10.14412/1995-4484-2018-1-29

For citation:


Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P., Alekseeva L.I., Abuzarova G.R., Evseev M.A., Kukushkin M.L., Kopenkin S.S., Lila A.M., Lapina T.L., Novikova D.S., Popkova T.V., Rebrov A.P., Skorobogatykh K.V., Chichasova N.V. RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29

Просмотров: 1097


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)